0
0
Revolutionizing Cancer Care with AI Solutions
Amid ongoing debates surrounding the integration of artificial intelligence (AI) in healthcare, startups are embracing this technology with fervor and support from venture capital firms. Today, the spotlight is on San Francisco-based startup Triomics, which aims to expedite cancer care through generative AI. The company has secured $15 million in funding from prominent investors such as Lightspeed, Nexus Venture Partners, General Catalyst, and Y Combinator.
Founded by Sarim Khan and Hrituraj Singh, former researchers at MIT and Adobe, Triomics has developed a suite of large language models (LLMs) known as OncoLLM. These models, designed to optimize oncology-related workflows, enable medical center staff to efficiently navigate the complexities of determining the most appropriate treatment for cancer patients.
One of the key advantages of OncoLLM is its ability to expedite tasks that typically require days or weeks to complete, accomplishing them within minutes. By leveraging a combination of specialized tools and expertise, Triomics has successfully bridged the gap between AI research and clinical oncology, resulting in a software solution tailored to the intricate nuances of cancer research and patient care.
Solving Critical Challenges in Oncology
The global healthcare landscape is witnessing a steady rise in cancer cases, with projections indicating a 77% increase in new cases by 2050 compared to 2022. This surge in cancer diagnosis poses significant challenges for medical institutions, particularly in light of the growing demand for personalized care and treatment.
Currently, healthcare providers rely on manual chart reviews to determine suitable care pathways and clinical trial eligibility for cancer patients. This process is labor-intensive and time-consuming, often leading to delays in essential treatment decisions. Triomics addresses this issue by offering OncoLLM, a specialized model that can be fine-tuned using internal datasets, empowering medical centers to streamline their workflow automation processes.
According to Khan, the versatility of OncoLLM allows for customization based on each provider’s unique data, ensuring optimal performance and tailored outcomes for partner institutions. By integrating OncoLLM into its software solutions, namely Harmony and Prism, Triomics facilitates data curation, patient-trial matching, and overall efficiency in patient care management.
During a trial conducted at the Medical College of Wisconsin Cancer Center, OncoLLM demonstrated superior performance in patient-trial matching compared to established LLMs and even qualified medical experts. Notably, Triomics has further enhanced its model with the introduction of OncoLLM (70B), surpassing industry benchmarks in accuracy while remaining cost-effective.
Accelerating Growth and Impact
With a fresh infusion of funding, Triomics is poised to expand its team and enhance product scalability. The company aims to forge partnerships with academic institutions and community oncology practices, with a focus on increasing its customer base and making a meaningful impact on cancer care delivery.
While acknowledging the competitive landscape, Khan emphasizes Triomics’ specialization in oncology and the transformative potential of its AI-powered solutions. By prioritizing gen AI-native technologies and scalability, Triomics aims to set new benchmarks in oncology care and drive significant ROI for the industry.
Image/Photo credit: source url
